Skip to main content

Table 1 Baseline patients’ characteristics of 1860, LEAD-6 and Greek simulated cohorts

From: Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece

  1860 LEAD-6 Greek*
Patient demographics    
Baseline age (years) 55.3 (9.2) 56.7 (10.3) 64.5 (10.5)
Duration of diabetes (years) 6 (5.1) 8.2 (6) 10.4 (8.3)
Percentage male 52.9% 51.9% 51.5%
Baseline risk factors    
HbA1c (%) 8.4 (0.8) 8.2 (1.0) 8.2 (1.8)
Systolic blood pressure (mmHg) 132.2 (14.5) 133.0 (16.6) 139.8 (19.3)
Total cholesterol (mmol/l) 4.79 (0.38) 4.7 (0.95) 5.5 (−)
HDL (mmol/l) 1.16 (0.31) 1.2 (0.3) 1.2 (0.3)
LDL (mmol/l) 2.65 (0.82) 2.95 (0.8) 3.7 (1.0)
Triglycerides (mmol/l) 2.38 (2.22) 2.15 (1.35) 1.9 (1.4)
Body mass index (kg/m2) 32.8 (5.2) 32.9 (5.7) 30.4 (5.3)
Proportion smoker 36.0% 36.0% 36.0%
Cigarettes per day 18.7 18.7 18.7
Alcohol consumption (Oz/week) 15.91 15.91 15.91
Racial characteristics    
Proportion White 90% 80.6% 100%
Proportion Black 7.5% 5.5% 0%
Proportion Hispanic 0% 12.4% 0%
Proportion Native American 0.5% 1.3% 0%
Proportion Asian/Pacific Islander 2% 0.2% 0%
Baseline CVD complications    
Proportion with myocardial infarction 2.7% 2.6% 12.8%
Proportion with angina 1.8% 1.9% 5.0%
Proportion with peripheral vascular disease 0.9% 0.6% 5.6%
Proportion with stroke 0.8% 0.2% 8.1%
Proportion with congestive heart failure 0.4% 1.5% 4.2%
Proportion with atrial fibrillation 1.5% 1.5% 9.1%
Proportion with left ventricular hypertrophy 0.2% 0.2% 3.1%
Baseline renal complications    
Proportion with microalbuminuria 1.1% 1.1% 1.1%
Proportion with gross proteinuria 0.2% 0.2% 0.2%
Proportion with end-stage renal disease 0.4% 0.6% 0.4%
Baseline retinopathy complications  
Proportion with BDR 2.7% 1.1% 25%
Proportion with PDR 0.2% 0.2% 4%
Proportion with severe vision loss 0.4% 0.6% 4.5%
Baseline macular edema    
Proportion with macular edema 1.1% 0.2% 1.1%
Baseline cataract    
Proportion with cataract 1.7% 6.9% 1.7%
Baseline foot ulcer complications    
Prop. uninfected ulcer 0.6% 0.2% 0.6%
Prop. infected ulcer 0.3% 0.0% 0.3%
Prop. healed ulcer 0.0% 0.0% 0.0%
Prop. history of amputation 0.0% 0.2% 0.0%
Baseline neuropathy    
Proportion with neuropathy 11.6% 7.8% 14.7%
Baseline depression    
Proportion with depression 0% 0% 9%
  1. Data are mean (SD). *In the Greek cohort, all demographic and physiological parameters were retrieved from S. Liatis et al. study [13], while the renal, foot ulcer, macular oedema and cataract complications values were assumed to be the same as for 1860 cohort. All other diabetes-related complications were taken from National School of Public health (data on file) and racial characteristics from Hellenic Statistical Authority (http://www.statistics.gr). Considering all cohorts, the smoking status and number of cigarettes per day were elicited from National School of Public health, Healthcare map 2011 (data on file), whereas the alcohol consumption estimate from S. Liatis et al. study [13]. Proportion with depression assumed to be 0 in 1860 and LEAD-6 cohorts. Liraglutide Effect and Action in Diabetes 6 = LEAD-6; HbA1c = glycated haemoglobin; HDL = high-density lipoprotein; LDL = low-density lipoprotein; CVD = cardiovascular disease; BDR = background diabetic retinopathy; PDR = proliferative diabetic retinopathy.